If you are wondering whether Novavax at around US$7.25 is a bargain or a value trap, you are not alone. This article focuses on what the current price really implies about the company. The stock has ...

The JN.1 Novavax vaccine is an alternative to the LP.8.1 Pfizer-BioNTech and Moderna vaccines that were rolled out in October ...

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 3% in the morning session after reports ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...

(Reuters) -Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership ...

What is shaping interest in Novavax today? Novavax (NVAX) is back on many watchlists after recent trading moves, with the stock now priced around $7.25. For investors, the key question is how current ...

Novavax, Inc. reported a 3Q25 EPS loss and declining revenue, but beat revenue expectations and reaffirmed its FY25 guidance, driven by Sanofi partnership milestones. Novavax's heavy reliance on ...

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to ...

An additional dose can increase protection against severe disease, CDA said. Read more at straitstimes.com. Read more at ...